Sedat ÇİFTEL, Nihat OKÇU, HAKAN DURSUN, FATİH ALBAYRAK, Serpil USTA

Bölgemizde Helicobacter pylori sıklığı

Giriş ve Amaç: Bu çalışmanın amacı, Erzurum bölgesinde endoskopi yapılan hastalarda Helicobacter pylori (H.pylori) sıklığının araştırılarak yıllara göre sıklığındaki değişiklikleri göstermektir. Gereç ve Yöntem: Şubat-Ekim 2015 tarihleri arasında, endoskopi ünitemizde dispeptik şikayetle başvuran hastalardan, endoskopik antrum ve korpus biyop- sisi alınan hastalar, çalışmaya alındı ve retrospektif olarak incelendi. Hastaların H.pylori sıklıkları, cinsiyete göre ve yaş gruplarına ayrılarak belirlendi. Antrum ve korpus biyopsileri üre içeren besiyerine alınarak hasta başı inkübe edildi. 1.saat ve 24. saatlik inkübasyon sürelerinde, besiyerinin pH indikatörü ile sarıdan pembeye ve mor renge doğru renk değişikliğine bakıldı. Pozitif olgularda genellikle ilk 1 saat içinde sonuç alınır. Negatif olanlarda ise duyarlılığı artırmak için inkübasyon süresini uzatmak gerekir. Bu testin duyarlılığı, bir saat içinde %60-90 iken, 24 saatte ise duyarlılık %90'dan fazladır. Bulgular: Antrum biyopsisi alı- nan 653 hasta çalışmaya alındı. Bu hastaların 268'i (%41) erkek olup, yaş ortalaması 47.5±16.05 yaş idi. Hastaların 377'sinde (%57.7) H.pylori pozitif, 276'sında (%42.2) negatif idi. H.pylori pozitif saptanan hastaların yaklaşık %58.7'sinde hafif (+), %41.2'sinde şid- dettli (++) pozitiflik olarak rapor edildi. Kadınlarda ve erkeklerde sıklık benzer olup sırasıyla %57.6 ve %57.8' idi. 20 yaş altı, 21-40 yaş, 41-60 yaş, 60 yaş üstü yaş gruplarında, H.pylori sıklığı sırasıyla, %56.2, %57.7, %59.2 ve %57.3 idi. Sonuç: Erzurum bölgesinde, H.pylori sıklığı %57.7 olup yıllara göre sıklıkta azalma izlenmektedir. H. pylori sıklığı açısından, cinsiyet ve yaş grupları arasında anlamlı farklılık bulunmamıştır

Helicobacter pylori prevalance in our region

Background and Aims: The aim of this study is to investigate the prev- alence of Helicobacter pylori and the change of prevalence by years in patients underwent endoscopy eastern Anatolia. Materials and Meth- ods: The patients whose endoscopic antrum and corpus biopsies were taken for dyspeptic symptoms in our endoscopy unit in February-Octo- ber 2015 period were included and retrospectively investigated. The frequency of Helicobacter pylori was determined as separating the patients according to general, sex and the age groups. Antrum and corpus biopsies were stained with urea and incubated per patient. In 1 st hour and 24 th hour incubation periods, it is looked for transitions in the color from yellow to purple and pink by a PH indicator. In positive cases, we can generally get a result in the first hour. In negative ones, to increase the sensitivity, it has to be make the incubation period lon- ger. Although the sensitivity of this test 60-90 % in an hour, it is more than 90% in 24 hours. Results: Biopsy specimens of 653 patients were included into the study. The mean age was 47.5±16.05 years and 268 of these patients (41%) were male. 377 of the patients (57.7%) were positive and 276 (42.2%) were negative for Helicobacter pylori. It was reported that 58.7% of those patients had mild positive, 41.2% of those had severe positive in infected by Helicobacter pylori. No significant difference was found in the frequency of Helicobacter pylori between women and men, 57.6% and 57.8% respectively. The frequencies of Helicobacter pylori were 56.2%, 57.7%, 59.2% and 57.3%, respectively, in the age groups of under 20 years, 21-40 years, 41-60 years and older 60 years. Conclusion: The frequency of Helico- bacter pylori was 57.7% in Erzurum Region and it is observed that it is decreasing in the during the years. No statistically significant difference was found between genders and age groups in term of the frequency of Helicobacter pylori

PDF

___

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
2. Altintaş E, Ulu O, Sezgin O, et al. Comparison of ranitidine, bismuth citrate, tetracycline and metronidazole with ranitidine, bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy. Turk J Gastroenterol 2004;15:90-3.
3. Köksal AS, Onder FO, Torun S, et al. Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance. Acta Gastroenterol Belg 2013;76:34-7.
4. Zheng Q, Chen WJ, Lu H, et al. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. J Dig Dis 2010;11:313-8.
5. Brooks GF, Butel JS, Morse SA. Jawetz Melnick and A delberg’s Medical Microbiology. 21st ed. Connecticut: Appelet on and Lange, 1998:543-65.
6. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720-41.
7. [No authors listed]. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
8. IARC Helicobacter pylori Working Group. Helicobacter Pylori Eradication as a Strategy for Preventing Gasric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group reports, no.8); 2014. Available from: http://www.iare.fr/en/publications/pdfs-online/wrk/wrk8/index.php./Last accessed 2015 Aug2)
9. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
10. Malfertheiner P, Megraud F, O’ Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection-The Maastricht IV/Florence Consensus Report. Gut 2012; 61:646-64.
11. Graham DY, Malaty HM, Evans DG, et all. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991;100:1495-501.
12. Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother 2013;14:211-23.
13. Özkan TB. Çocuklarda Helicobacter pylori enfeksiyonunda seroloji, tanı ve tedavi. Uludağ Üni Tıp Fak Derg 2007;33:81-5.
14. Moya DA, Crrisinger KD. Helicobacter pylori persistence in children: distinguishing inadequate treatment, resistant organisms, and reinfection. Curr Gastroenterol Rep 2012;14:236-42.
15. Fidan I, Türet S. Helicobacter pylori enfeksiyonunda patogenez ve tanı. Enfeksiyon Dergisi 1999;13:455-460.
16. Ozaydin N1, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the 13C-Urea breath test. BMC Public Health 2013;13:1215.
17. Ozden A, Bozdayı G, Ozkan M, Kose KS. Changes in the seroepidemiyological pattern of Helicobacter pylori infection over the last 10 years in Turkey. Turk J Gastroenterol 2004;15:156-8.
18. Syam AF, Miftahussurur M, Makmun D, et al. Risk factors and prevalence of Helicobacter pylori in five largest islands of Indonesia: a preliminary study. PLoS One 2015;10:e0140186.
19. Açık Y, Gülbayrak C, Dönder E, Yalnız M. Fırat Tıp Merkezine dispeptik yakınmalarla başvuran hastalarda Helicobacter pylori sıklığı ve etkileyen faktörler. OMÜ Tıp Dergisi 2003;20:82-8.
20. Veldhuyzen-von-Zonten SJ, Pollak PT, Best LM, et al. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J infect Dis 1994;169:434-7.
21. Uyanıkoğlu A, Coşkun M, Binici DN, ve ark. Endoskopi yapılan hastalarda Helicobacter pylori sıklığı. Dicle Tıp Derg 2012;39:197-200.
22. Çıkman A, Parlak M, Güdücüoğlu H, Berktaş M. Van yöresinde Helicobacter pylori prevalansı, yaş ve cinsiyete göre dağılımı. Ankem Derg 2012;26:30-4.
23. Yücel T, Aygin D, Şen S, Yücel O. The prevalence of Helicobacter pylori and related factors among university students in Turkey. Jpn J Infect Dis 2008;61:179-83.
24. Ferlay J, Soerjjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: souces, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.